Sitting down with… Neil Dhawan
Drug Discovery World
AUGUST 10, 2023
The study is currently enrolling in the US with European sites planned to open later in 2023. ND : In 2023 at Totus, we have the opportunity to prove the power of our platform with the most important form of data – clinical data. Eligible subjects are adults with PI3Kα-mutant tumours. At Totus we say, “The more data, the better!”
Let's personalize your content